Recursion Pharmaceuticals ( RXRX +1.27%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Recursion announced Najat Khan, PhD, currently chief R&D and commercial officer and a board member, will succeed co-founder and CEO Chris Gibson, PhD as CEO and president. Khan will also continue in ...

Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Abstract: Multi-modal image synthesis is crucial for obtaining complete modalities due to the imaging restrictions in reality. Current methods, primarily CNN-based models, find it challenging to ...

Recursion Pharmaceuticals (RXRX) saw a sharp uptick in trading as investors looked ahead to the CEO's upcoming presentation at a major AI conference. The focus is on how the company’s AI strategy and ...